Results 131 to 140 of about 3,710 (152)

Clinical Updates in Pulmonary Hypertension. [PDF]

Rev Cardiovasc Med
Diaz G, Lawrence A, Ossi J, Arungwa D, Weiss A, Virk HUH, Khawaja M, Krittanawong C.   +7 more
europepmc   +1 more source

Exploring the therapeutic landscape of pulmonary hypertension associated with interstitial lung disease, with a focus on idiopathic pulmonary fibrosis: a narrative review. [PDF]

Front Pharmacol
Reccardini N, Da Re B, Mondini L, Salton F, Confalonieri M, Confalonieri P, Hughes M, Monteleone G, Ruaro B.   +8 more
europepmc   +1 more source

ECMO-supported intervention for chronic centrally occluded pulmonary arteries. [PDF]

Cardiovasc Interv Ther
Taha HSE, Younis O, Mamdouh M.
europepmc   +1 more source

Pharmacovigilance assessment of gout: a real-world study using the FAERS database. [PDF]

Front Pharmacol
Ren H, Yao N, Ren X, Su Y, Yao H, Hu J, Wen P, Zhang M, Xu P, Hou W, Yang Z, Yang M.   +11 more
europepmc   +1 more source

Intravenous Treprostinil in Precapillary and Postcapillary Pulmonary Hypertension Due to Cardiac Amyloidosis and Aortic Stenosis. [PDF]

JACC Case Rep
Schramm H, Steringer-Mascherbauer R, Mascherbauer J.   +2 more
europepmc   +1 more source

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry [PDF]

Respiratory Medicine, 2021
Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH ...
Ioannis Stanopoulos, Stavros Konstantinides, Henning Gall   +2 more
exaly   +13 more sources

Some of the next articles are maybe not open access.

Related searches:

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

Respiratory Medicine, 2021
Ioannis Stanopoulos, George Giannakoulas, Marion Delcroix   +2 more
exaly  

Determination and pharmacokinetic study of riociguat by UPLC-MS/MS in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022
Ömer Faruk Kocak, Yucel KADIOGLU, Alptug Atila   +2 more
exaly  

Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension

Journal of Heart and Lung Transplantation, 2023
Stefan Guth, Miriam Sin Dorothea Adameit, Andreas Breithecker   +2 more
exaly  

Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension

Pulmonary Circulation, 2018
Yuji Itabashi, Masaharu Kataoka, Takashi Kawakami   +2 more
exaly